Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | S100A4 | P26447 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926046 | 0.85 | TSHR (0.71) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL118464 | 0.85 | TSHR (0.71) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28529002 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7157907 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| Fluoride SCHEMBL29099623 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL7157905 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29669769 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| Hydrogen Sulfide SCHEMBL28144547 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL27735242 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 | |
| Water SCHEMBL27294140 | 0.83 | TSHR (0.68) | TSHRGPR35TDP1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| US-20230312471-A1 | CHEMICAL PROBES AND INHIBITORS FOR POLYPEPTIDES OF SARS CORONAVIRUSES | Universität Konstanz (DE) | 2023-10-05 | — | — | US | claimed |
| EP-4204089-A1 | CHEMICAL PROBES AND INHIBITORS FOR POLYPEPTIDES OF SARS CORONAVIRUSES | Universität Konstanz (DE) | 2023-07-05 | — | — | EP | claimed |
| WO-2023118378-A1 | NOVEL GLYCOSYNTHASE | CARBOCODE S.A. (PT) | 2023-06-29 | — | — | WO | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115443134-A | Conjugates of cell binding molecules and camptothecin analogs | 杭州多禧生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-113195487-A | 2, 3-diaminosuccinyl conjugate linkers | 杭州多禧生物科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| CN-112272669-A | Cross-linked pyrrolobenzodiazepine dimer (PBD) derivatives and conjugates thereof | 杭州多禧生物科技有限公司 | 2021-01-26 | — | — | CN | claimed |
| US-9982018-B2 | Amatoxin derivatives | HEIDELBERG PHARMA GMBH (DE) | 2018-05-29 | — | — | US | claimed |
| EP-0186576-B1 | COVALENTLY-MODIFIED NEUTRAL BACTERIAL POLYSACCHARIDES, STABLE COVALENT CONJUGATES OF SUCH POLYSACCHARIDES AND IMMUNOGENIC PROTEINS, AND METHODS OF PREPARING SUCH POLYSACCHARIDES AND CONJUGATES | MERCK & CO. INC. (US) | 1992-07-22 | — | — | EP | claimed |
| EP-0161188-B1 | COVALENTLY-MODIFIED BACTERIAL POLYSACCHARIDES, STABLE COVALENT CONJUGATES OF SUCH POLYSACCHARIDES AND IMMUNOGENIC PROTEINS WITH BIGENERIC SPACERS, AND METHODS OF PREPARING SUCH POLYSACCHARIDES AND CONJUGATES AND OF CONFIRMING COVALENCY | MERCK & CO. INC. (US) | 1991-04-03 | — | — | EP | claimed |
| US-4882317-A | SOLUBILIZATION | MERCK & CO., INC. (US) | 1989-11-21 | — | — | US | claimed |
| EP-0186576-A2 | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates | MERCK & CO. INC. (US) | 1986-07-02 | — | — | EP | claimed |
| EP-0161188-A2 | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | claimed |
| US-4487963-A | Enantioselective synthesis of 4-amino-3-hydroxy-2,4-(disubstituted)pentanoic acid | MERCK & CO., INC. (US) | 1984-12-11 | — | — | US | claimed |
| EP-0042731-B1 | LARVICIDES, INSECTICIDES, ACARICIDES AND MITICIDES, PROCESSES FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1984-12-05 | — | — | EP | claimed |
| EP-0023343-B1 | SUBSTITUTED 3-AMINO-SYDNONIMINES, PROCESS FOR THEIR SYNTHESIS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1984-03-28 | — | — | EP | claimed |
| EP-0042731-A1 | Larvicides, insecticides, acaricides and miticides, processes for preparing them and compositions containing them | Pfizer Limited (GB) | 1981-12-30 | — | — | EP | claimed |
| EP-0023343-A2 | Substituted 3-amino-sydnonimines, process for their synthesis and pharmaceutical preparations containing them | CASSELLA Aktiengesellschaft (DE) | 1981-02-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312471-A1 | CHEMICAL PROBES AND INHIBITORS FOR POLYPEPTIDES OF SARS CORONAVIRUSES | SARS1, ACE, ACE2 | TSHR 2697/4885GPR35 2629/4885TDP1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.